Shows
The Onco'Zine BriefCOVID-19 and the Impact of Cryopreservation on Hematopoietic Cell GraftsIn this episode of The Onco’Zine Brief Peter Hofland talks with Stephen Spellman. Stephen Spellman is Vice President and Senior Scientific Director at Be The Match and the Center for International Blood & Marrow Transplant Research (CIBMTR). Hofland and Spellman talk about the outcomes of a study published in Blood Advances, the journal of the American Society of Hematology. [1] The article discusses the impact of cryopreservation of hematopoietic cell grafts on overall survival (OS) and other outcomes within 1 year after hematopoietic cell transplantation. At the beginning of the COVID-19 pandemic the National Marrow Donor Pr...2023-11-3045 minThe Onco'Zine BriefBe The Match®: Improving Outcomes and Providing Hope to Patients in NeedIn a new episode of The Onco’Zine Brief, Peter Hofland talks with Jeffery Auletta, MD is Senior Vice President, Patient Outcomes and Experience, National Marrow Donor Program® (NMDP)/Be The Match®.Be The Match® is a global leader in bone marrow transplantation. The organization conducts research to improve transplant outcomes provide support and resources for patients, and partner with a global network.Unmet medical needEvery three or four minutes, someone in the United States is diagnosed with a hematological malignancy such as leukemia, a cancer of blood-forming tissues, including bone marrow....2023-09-2852 min
The Onco'Zine Brief with Peter HoflandDeveloping a New Standard of Care Cancer Treatment with PhotoimmunotherapyIn this episode of The Onco'Zine Brief, Peter Hofland talks with David M. Cognetti, MD, a Professor and Chair in the Department Head and Neck Surgery at Thomas Jefferson University Hospital in Philadelphia.
Hofland and Cognetti talk about head and neck cancer and a novel treatment approach called Photoimmunotherapy.
According to the American Cancer Society, Head and neck cancer accounts for about 4% of all cancers in the United States. In the United States in 2023, an estimated 67,000 people will be diagnosed with head and neck cancer and about 15,000 patients are expected to die of the disease.
Today, many cancers of the...2023-08-1841 minThe Onco'Zine Brief with Peter HoflandHighlights from ASH: Conversations with Christopher Heery and Srdan VerstovsekIn this episode of The Onco'Zine Brief, Peter Hofland talks with two experts about their research and the impact the outcomes from these studies may have on the treatment of patients diagnosed with cancer.
First, Hofland talks with Christopher Heery, MD.
Dr Heery is a board-certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, including, but not limited to PD-L1 inhibitors, therapeutic cancer vaccines, immune suppressor modulator, adoptive NK cells, and other therapeutics.
As the chief medical officer at https://www.arcellx.com/, he is responsible for medical oversight, clinical strategy, medical affairs, and regulatory...2023-07-3044 minThe Onco'Zine Brief with Peter HoflandHighlights of ASH: Conversation about Multiple Myeloma with Thomas Martin and Monica SoniIn December 2022 the annual meeting of the American Society of Hematology took place in the vibrant city of New Orleans and brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from initial hypothesis to practice-changing results.
In this episode of The Onco’Zine Brief Peter Hofland talks to two people about their research and the impact the outcomes from these studies may have.
First, Hofland talks with Thomas G. Martin, MD.
Martin is the Associate Director of the University of California San Francisco Myeloma Program and Director of th...2023-05-1741 minThe Onco'Zine BriefHighlights from ASH: Conversations with Christopher Heery and Srdan VerstovsekIn this episode of The Onco'Zine Brief, Peter Hofland talks with two experts about their research and the impact the outcomes from these studies may have on the treatment of patients diagnosed with cancer.First, Hofland talks with Christopher Heery, MD.Dr Heery is a board-certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, including, but not limited to PD-L1 inhibitors, therapeutic cancer vaccines, immune suppressor modulator, adoptive NK cells, and other therapeutics.As the chief medical officer at Arcellx, he is responsible for medical oversight, clinical strategy, medical...2023-04-1644 minThe Onco'Zine Brief with Peter HoflandA Fantastic Voyage: From Magic Bullet to Antibody-drug ConjugateIn this –this episode of the Onco’Zine Brief, Peter Hofland is talking with Dr. Matthias Bucerius.
Dr. Bucerius is Vice President and General Manager at MilliporeSigma. He is responsible for Contract Development and Manufacturing Organsation (CDMO) business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations.
The company is helping its clients in developing and manufacturing a variety of products, including antibody-drug conjugates. Antibody-drug conjugates or ADCs are targeted therapies that have opened new ways in targeting diseases like cancer and hematological malignancies.
What is unique about ADCs is that they...2023-03-1644 minThe Onco'Zine BriefHighlights from ASH: Conversations about Multiple Myeloma with Thomas Martin and Monica SoniIn December 2022 the annual meeting of the American Society of Hematology took place in the vibrant city of New Orleans and brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from initial hypothesis to practice-changing results.In this episode of The Onco’Zine Brief Peter Hofland talks to two people about their research and the impact the outcomes from these studies may have.First, Hofland talks with Thomas G. Martin, MD.Martin is the Associate Director of th...2023-02-1741 min
The Onco'Zine Brief with Peter HoflandMismatched Unrelated Donors: A Key to Erasing the Gap in Donor Availability in HCTIn this – the 100th episode of the Onco’Zine Brief, Peter Hofland, Ph.D. talks with Stephen Spellman, Vice President of Research and Senior Scientific Director of the Center for International Blood and Marrow Transplant Research at the National Marrow Donor Program/Be the Match.
In the program today Hofland and Spellman talk about bone-marrow transplants.
The likelihood of finding a fully matched unrelated donor for a patient who needs a bone marrow transplantvaries greatly depending on a patient’s ethnic background, and that ethnically diverse patients have – historically – been at a disadvantage. However, new research shows that when donor registry m...2023-01-1941 minThe Onco'Zine Brief with Peter HoflandSusanna Greer, Ph.D: Advancing Funding for Cutting-edge Cancer ResearchIn this edition of The Onco'Zine Brief, Peter Hofland, Ph.D, talks with Susanna F. Greer, Ph.D. the Chief Scientific Officer of the V Foundation. In her role, Dr. Greer is a visionary ambassador of the V Foundation, who works with the foundation’s Scientific Advisory Committee to steer funding to the most promising research opportunities.
An accomplished strategist, she develops and articulates priorities to enhance the V Foundation’s research portfolio, gifts, grants, and sponsorships that advance the V Foundation’s distinctive brand of cutting-edge and disruptive research.
The V Foundation was founded in 1993 by ESPN and the late J...2022-12-0148 minThe Onco'Zine Brief with Peter HoflandA Novel Approach to Advancing Breast Cancer TherapyDespite availability of endocrine therapies for advanced or metastatic breast cancer, there remains a critical unmet need for more effective and convenient treatment options that improve both the patient experience and health outcomes.
In today’s episode of The Onco’Zine Brief, Peter Hofland, Ph.D. talks with Sean P. Bohen, MD, Ph.D., the president and Chief Executive Officer of Olema Therapeutics.
Olema Terapeutics is developing new treatment options designed to improve outcomes for women with metastatic breast cancer. The company’s lead investigational drug is OP-1250.
This drug is a is a novel agent with combined activity as both a...2022-10-2739 minThe Onco'Zine Brief with Peter HoflandESMO 2022: Advances in the Treatment of CancerThe annual congress of the European Society for Medical oncology or ESMO, is one of the most influential oncology meetings for clinicians, researchers, patient advocates, and healthcare industry representatives from all over the world. This year the annual Congress was held September 9 - 13, 2022 in the Paris Expo Porte de Versailles in Paris, France.
In this episode of the Onco’Zine Brief, Peter Hofland, Ph.D., talks with:
- Eric Vivier DVM, Ph.D, senior vice president and scientific officer of Innate Pharma about anti-cancer drugs designed to harness the power of Natural Killer (NK-) Cells. During the ESMO Congress, the co...2022-10-0449 minThe Onco'Zine Brief with Peter HoflandRedefining the Rules of Cancer TreatmentGlioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. And while the disease can occur at any age, it tends to occur more often in older people.
According to the American Cancer Society, United States, doctors diagnose between 12,000 and 14,000 patients with glioblastoma in the U.S. each year. There is currently no cure for glioblastoma. The median length of survival after a diagnosis is 15-
18 months, while the disease’s five-year survival rate is around 10%.
And while all glioblastomas recur, initial treatments may keep the tumor controlled
for months or even years.
To im...2022-09-0145 minThe Onco'Zine Brief with Peter HoflandValena Weight, MD - It's Time You Knew, The Power of Your Choices to Prevent Women's CancerYour annual doctors – or wellness visit may not be enough to prevent diseases like cancer. Daily health and lifestyle choices are the key to cancer prevention --but what are these choices? What is important?
In "It’s Time you Knew’ - The Power of Your Choices to Prevent Women's Cancer", board certified gynecological oncologist Dr Valene Wright offers simple and straightforward tools to help women listen to their own body – and in doing so take control of their own health.
In this episode Peter Hofland PhD talks with board certified gynecological oncologist and surgeon Valene Wright, MD. In her book, Wright h...2022-07-1446 minThe Onco'Zine Brief with Peter HoflandLynch Syndrome and Genetic TestingAfter checking your cholesterol, hemoglobin A1C, and glucose level during your annual wellness check, your primary care phycisian says: 'It looks like we haven't done your genome. Why don't we do that?' How would you respond? If you have a genetic mutation that increases your risk for a treatable medical condition, would you want to know? For many people the answer is yes. But typically, such information has not been a part of routine primary care.
In this episode Peter Hofland PhD talks with Noelle Carbognin and Elizabeth Chao, MD, FACMG, a Medical Geneticist at UC Irvine about...2022-06-0248 minThe Onco'Zine Brief with Peter HoflandMarie E. Lamont: Lessons Learned during the COVID-19 Pandemic helps in Transforming Patient Access to Clinical TrialsResearch out earlier this year confirms what many doctors had feared: Cancer
screenings dropped significantly during the Covid-19 pandemic.
The study, published in the February 2022 edition of Journal of the National
Comprehensive Cancer Network, examined data from the Ontario Cancer Registry in
Canada. The results showed that in March 2020 the week-to-week rate of cancer diagnosis dropped by 34.3%. And this worries doctors, because over the last few decades, the
cancer survival rates have improved, in part because of earlier detection of disease. [1]
Doctors fear that this disruption to healthcare access may negatively impact early detection of cancers which may lead to...2022-05-0448 minThe Onco'Zine Brief with Peter HoflandSABCS 2021: Key Findings in Breast Cancer ResearchIn the past 30 years, the survival rate for breast cancer has improved by about 40%, one of the highest survival rates of any cancer. The increase in survival is, in part, due to advances in screening technology as well as improvement in cancer treatment and a better understanding of the biology of cancer. All of which have had an impact on survival.
In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with talking with Stephen Malamud, MD, who is the regional director of medical oncology at Nuvance Health, a health network with hospitals, medical practices, and care ce...2022-01-1149 minThe Onco'Zine BriefSABCS 2021: Key Findings in Breast Cancer ResearchIn the past 30 years, the survival rate for breast cancer has improved by about 40%, one of the highest survival rates of any cancer. The increase in survival is, in part, due to advances in screening technology as well as improvement in cancer treatment and a better understanding of the biology of cancer. All of which have had an impact on survival.In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with talking with Stephen Malamud, MD, who is the regional director of medical oncology at Nuvance Health, a health network with hospitals, medical practices, an...2022-01-1149 minThe Onco'Zine Brief with Peter HoflandWorking Tirelessly to Improve the Lives of Cancer PatientsCancer remains the second leading cause of death in the world, and numbers are on the rise. To respond to the growing need for therapeutic solutions, much research is needed. In this episode of The Onco’Zine BriefPeter Hofland, Ph.D. talks with Susan Pandya, MD.
Pandya is Vice President Clinical Development and Global Head of Cancer Metabolism at Servier Pharmaceuticals. She is also a board-certified Hematologist-Oncologist and a master clinician with a passion for innovation in cancer treatment. In her current role as Vice President of Clinical Development at Servier Pharmaceuticals Pandya is overseeing hematology and oncology clinical development pr...2021-12-1147 minThe Onco'Zine Brief with Peter HoflandA Novel, First-in-class, Photodynamic Therapy for Patients with CTCLIn this episode of The Onco’Zine Brief Peter Hofland Ph.D. talks with Ellen J. Kim, MD. Kim is the Medical Director of the Dermatology Clinic at the Perelman Center for Advanced Medicine and Professor of Dermatology at the Hospital of the University of Pennsylvania. She is also the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL). This study is the largest multicenter, randomized, double-blind, placebo-controlled, skin-directed therapy study in cutaneous T-cell lymphoma, to date, enrolling a total of 169 patients.
In our program today Hofland and Kim talk about th...2021-11-2345 minThe Onco'Zine Brief with Peter HoflandA Promising Treatment Option for Patients Diagnosed with Head-and-neck CancerIn this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Eyal Talor, Ph.D., a clinical immunologist with over 25 years of hands-on management experience in clinical research and drug development. Talor joined CEL-SCI in October 1993 and was promoted to Chief Scientific Officer in October 2009. CEL-SCI is developing a new immunotherapeutic drug for the treatment of cancer, autoimmune diseases, and infectious diseases. In today’s program, Hofland and Talor are talking about one of these agents, an investigational drug called leukocyte interleukin, or Multikine®
Multikine® is currently in late-stage development and is being investigated as a possible new ad...2021-11-0248 minThe Onco'Zine Brief with Peter HoflandPRECEDE: Transforming the Early Detection and Prevention of Pancreatic CancerIn this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Diane Simeone, MD, the Committee Chair and Principal Investigator and Executive Committee Chair of the PRECEDE Consortium. Simeone is also the Laura and Isaac Perlmutter Professor of Surgery, Department of Surgery at NYU Grossman School of Medicine, Professor, Department of Pathology at NYU Grossman School of Medicine, Director, Pancreatic Cancer Center and Associate Director, Translational Research, Perlmutter Cancer Center.
Hofland also talks with Tom Schoenherr, the Chief Executive Officer of Ambry Genetics, one of the participating industry partners of the PRECEDE program.
In today’s episode Sime...2021-10-2148 minThe Onco'Zine BriefPRECEDE: Transforming the Early Detection and Prevention of Pancreatic CancerIn this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Diane Simeone, MD, the Committee Chair and Principal Investigator and Executive Committee Chair of the PRECEDE Consortium. Simeone is also the Laura and Isaac Perlmutter Professor of Surgery, Department of Surgery at NYU Grossman School of Medicine, Professor, Department of Pathology at NYU Grossman School of Medicine, Director, Pancreatic Cancer Center and Associate Director, Translational Research, Perlmutter Cancer Center. Hofland also talks with Tom Schoenherr, the Chief Executive Officer of Ambry Genetics, one of the participating industry partners of the PRECEDE program.In...2021-10-2148 minThe Onco'Zine Brief with Peter HoflandAdvancements in the Treatment of Glioblastoma: "More Drug is Not Always Better"In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Nader Sanai, MD.
Dr. Sanai is the director of the Ivy Brain Tumor Center and the director of neurosurgical oncology at the Barrow Neurological Institute in Phoenix, Arizona. In this episode of the program Hofland asked Sanai about Phase 0 studies – also known as micro-dosing studies – and why they are so important in the development of promising new drugs. They also talk about a potential, non-invasive treatment option for glioblastoma as well as and data he presented during the annual meeting of the European Society for Medical Oncolo...2021-10-0549 min
The Onco'Zine Brief with Peter HoflandAntibody-drug Conjugates: Coming of AgeIn this episode of The Onco’Zine Brief, developed in collaboration with ADC Review | Journal of Antibody-drug Conjugates (at www.ADCReview.com), Peter Hofland, Ph.D. talks with William (Bill) Newell, JD, Chief Executive Officer and a member of the Board of Directors of Sutro Biopharma (www.sutrobio.com)
Sutro is a clinical-stage drug discovery, development, and manufacturing company using precise protein engineering and rational design to advance the development of the next-generation oncology therapeutics for unmet medical needs and areas where the current standard of care is suboptimal.
To date, Sutro’s technology platform has led to the development of c...2021-06-2746 minThe Onco'Zine Brief with Peter HoflandHarnessing the Immune System to Fight Cancer: An Interview with Innate Pharma's Mondher MahjoubiIn this edition of The Onco’Zine Brief Peter Hofland, Ph.D., talks with Mondher Mahjoubi, MD, Chief Executive Officer and Chairman of the Executive Board of Innate Pharma, a clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical needs. The company, based in the South of France, has been a pioneer in the understanding of the biology of natural killer (NK-) cell, and has...2021-06-2738 minThe Onco'Zine Brief with Peter HoflandShaping the Possibilities for Patients Everywhere: A Conversation with Zymeworks' Tony PolverinoIn this edition of The Onco’Zine Brief Peter Hofland, Ph.D talks with Tony Polverino, Ph.D. In September 2918 Polverino joined Zymeworks, a clinical-stage, biopharmaceutical company developing next-generation multifunctional biotherapeutics. He currently serves as the company's Executive Vice President of Early Development and Chief Scientific Officer. Prior to joining Zymeworks, from 2015 until 2018, Polverino was at Kite Pharma, which was acquired by Gilead Sciences in 2017.
Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody that has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliar...2021-06-2746 minThe Onco'Zine Brief with Peter HoflandA New Way to Prevent Colon Cancer: A Conversation with Check-Cap's Yoav Kimchy, Ph.D.In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Yoav Kimchy, Ph.D.
Kimchy has more than 20 years of experience in the development and management of innovative medical device companies. He founded Check-Cap in 2005 and served as the company's Chief Technology Officer.
Check-Cap is a clinical-stage medical diagnostics company aiming to redefine colorectal cancer screening/ through the introduction of C-Scan®, the first patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer. The new screening technology is being designed to enable early intervention and cancer prevention.
The capsule-based screening technology is exp...2021-06-2640 minThe Onco'Zine Brief with Peter HoflandAdvancing the Diagnosis and Treatment of Ductal Carcinoma in Situ (DCIS)In this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Leonard Farber, MD, a board-certified Radiation Oncologist, and healthcare executive. Farber is recognized for his ability to identify ground-breaking technologies and position them for success in clinical practice. He recently joined EHMET Health, an emerging medical device company with a state-of-the-art device for providing radiation as a treatment for breast cancer, Farber joined the company as the Chief Medical Officer and Executive Vice President of Clinical Research. Farber also works with a large number of pioneering startups focusing on health and medicine, including establishments such as Pr...2021-06-2646 minThe Onco'Zine BriefDeveloping Transformative Therapies for Patients with Diffuse Large B-cell LymphomaIn this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Malte Peters, MD, Chief Research and Development Officer at MorphoSys, and Peter Langmuir, MD., Vice President, Oncology Drug Development at Incyte. In our program today, which was originally recorded in August 2020, Hofland, Peters, and Langmuir also talk about the companies and the transformative therapies they have developed for patients diagnosed with Diffuse Large B-cell Lymphoma that has come back or that did not respond to previous treatment and who cannot receive a stem cell transplant.Hofland, Peters, and Langmuir also talk about a...2021-02-0443 minThe Onco'Zine BriefAccelerate the Development of Precision Medicine DiagnosticsIn this edition of The Onco’Zine Brief Peter Hofland talks with Peter Keeling about Personalized Medicine, diagnostic testing, and the effect of Covid-19 on cancer and cancer diagnostics. Hofland and Keeling also talk about the world’s first Diagnostic Network for Precision Medicine.Peter Keeling is the chief executive officer and Founder of Diaceutics. Since its founding, the company has built the world’s largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries.The company recently launched the world’s first digital diagnostics platform solution. Diaceutics has launched this new platform...2020-11-1848 minThe Onco'Zine BriefThe Burden of Chemotherapy-induced MyelosuppressionIn this episode of The Onco’Zine Brief Peter Hofland Ph.D., talks with Raj Malik M.D. and Robert Epstein M.D.Malik is Chief Medical Officer and Senior Vice President, R&D, at G1 Therapeutics. He leads the company’s clinical development, medical affairs, regulatory affairs, biometrics, translational medicine and preclinical teams. Epstein is an epidemiologist with extensive expertise in pharmaco-economics and health outcomes research. He served in academia and public health prior to joining the private sector and is currently the Chief Executive Officer and co-Founder of Epstein Health, providing strategic consultancy services to life scie...2020-10-2746 min
The Onco'Zine Brief with Peter HoflandC3 – Looking for Ideas Beyond Medicine to Change Cancer CareIn this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Anthony Yanni, M.D., Senior Vice President, patient-centricity at Astellas. In this role, Yanni is responsible for leading the development and execution of Astellas’ global patient-centricity strategy.
To understand patient centricity, consider the fact that 10 years ago, patient-centricity wasn’t even a concept – In most cases, drugs were developed if scientists could achieve innovation, without considering if companies should actually develop a medicine based on the real-world unmet medical needs and the perspectives of the patient.
And while ‘patient-centricity’ has become an industry’s catchphrase, not everyone has t...2020-09-2247 min
The Onco'Zine Brief with Peter HoflandA Non-Invasive Blood Test Designed to Advance Infectious Disease DiagnosticsIn this episode of The Onco’Zine Brief Peter Hofland, Ph.D., talks with Tim Blauwkamp, Ph.D., Chief Scientific Officer and co-founder of Karius.
Karius, based in Redwood City, CA, has developed a non-invasive liquid biopsy, a blood test, called the Karius Test®. The test is based on next-generation sequencing of microbial cell-free DNA and can rapidly detect pathogens causing serious infections, including those diseases that are difficult to diagnose through conventional methods. The test can identify and quantify over 1,000 clinically relevant pathogens, including bacteria, DNA viruses, fungi, and parasites. The test can be used to identify infections related to...2020-08-2549 min
The Onco'Zine Brief with Peter HoflandDiagnosed with a Rare Cancer During the COVID-19 Pandemic? What Now?In this edition of The Onco’Zine Brief, Peter Hofland, Ph.D., talks with Vince McRuiz and Margo Shoup, MD, FACS.
Margo Shoup is a nationally recognized surgical oncologist who specializes in gastrointestinal cancers and sarcomas. She is also the senior vice president, and system chair of the Nuvance Health Cancer Institute, where she provides strategic and clinical leadership for all aspects of Nuvance Health’s cancer services.
Vince McRuiz is a patient of Dr. Shoup.
In March 2020 just as the COVID-19 pandemic was ramping up in the northeastern United States, Vince was diagnosed with a retroperitoneal sarcoma — a rare abdomi...2020-08-1747 min
The Onco'Zine Brief with Peter HoflandASCO 2020: New Developments in the Treatment of Hard to Treat CancersIn this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Christian Massacesi, MD, Senior Vice President, Head of Late Development Oncology R&D at AstraZeneca and with Jeffrey Skolnik, MD, Vice President, Clinical Development at Inovio Pharmaceuticals about new data and exciting developments both companies are presenting during the 2020 virtual annual meeting of the American Society of Clinical Oncology – ASCO.
This year, amidst the SAR-CoV-2 or coronavirus pandemic, the ASCO organization has been hard at work to offer a unique scientific program for oncology professionals, patient advocates, and industry representatives.
In the program, Hofland and Massacesi talk...2020-07-1246 min
The Onco'Zine Brief with Peter HoflandTransforming Cell Therapy Manufacturing by “Squeezing” Cells: An Interview with Armon ShareiIn this edition of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Armon Sharei, Ph.D. Chief Executive Officer of SQZ Biotech, about the development and manufacturing of cell therapies.
Traditionally, the foundation of cancer treatment included surgery, chemotherapy, and radiation therapy.
But over the last few decades, targeted therapies —drugs that specifically target molecular changes seen primarily on cancer cells—have become a standard treatment for many cancers.
In addition, over the past several years, immunotherapies—therapies that are designed to use the power of a patient's own immune system to attack cancer, have emerged as a new treatm...2020-07-1244 min
The Onco'Zine Brief with Peter HoflandAdvancing CAR T-cell Therapy in Difficult to Treat Cancers: An Interview with Precigen’s Helen SabzevariIn this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen.
Precigen is a biopharmaceutical company dedicated to the discovery and clinical-stage development of the next generation of gene and cell therapies using precision technology. The company is developing novel therapeutic agents that are designed to target the most urgent and difficult diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
During the second part of the virtual meeting of the American Association of Clinical Research – AACR - being held June 22 to June 24, 2020, the company presented preclinical results of an investigational drug called PRGN-3005 which...2020-07-0347 min
The Onco'Zine Brief with Peter HoflandSacituzumab Govitecan, a Novel Treatment for Patients with mTNBCIn this episode of The Onco'Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics. Hofland and Sperber talk about sacituzumab govitecan, a novel antibody-drug conjugate. At the time of the interview, the drug was not yet approved, but in the weeks following the interview, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan (Trodelvy™) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.
Sacituzumab govitecan, previously known as IMMU-132, is Immunomedics’ lead product and the...2020-06-1647 min
The Onco'Zine Brief with Peter HoflandSacituzumab Govitecan, a Novel Treatment for Patients with mTNBCIn this episode of The Onco'Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics. Hofland and Sperber talk about sacituzumab govitecan, a novel antibody-drug conjugate. At the time of the interview, the drug was not yet approved, but in the weeks following the interview, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan (Trodelvy™) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.
Sacituzumab govitecan, previously known as IMMU-132, is Immunomedics’ lead product and the...2020-06-1647 min
The Onco'Zine Brief with Peter HoflandCandid Conversations on Mets, Sex, and Side Effects: a Panel Discussion With Breast Cancer Oncologists, Women’s Health Experts and PatientsIn this edition of The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS), held December 10 - 14, 2019 in San Antonio, Texas, Peter Hofland talks with leading breast cancer experts, and patients about metastatic breast cancer and health related quality of life hrQoL issues including sexual intimacy, bone health and joint pain. In this roundtable, panelists will also discuss liquid biomarkers for disease progression in the metastatic setting.
The expert panel includes;
- David Portman, MD, founder and Chief Executive Officer (CEO) of Sermonix Pharmaceuticals. Portman is a respected Key Opinion Leader (KOL) in the field, presented cl...2019-12-2550 min
The Onco'Zine Brief with Peter HoflandSusan Rafte: A 25+ Year Survivor of Metastatic Breast Cancer and Patient AdvocateIn this episode The Onco’Zine Brief, recorded during the 42nd San Antonio Breast Cancer Symposium (SABCS) held December 10 – 14, 2019 in San Antonio, Texas, Peter Hofland talks with Susan Rafte, a 25+ year survivor of metastatic breast cancer and patient advocate.
In 1994, eight and a half months after birth to her daughter Marika, Susan Rafte, only 30 years old, was diagnosed with stage III ductal carcinoma.
While she was pregnant with her daughter, she first felt a lump in her breast. Her doctors attributed the lump to her pregnancies. However, 18 months later, when Rafte pushed for a biopsy, the lump was diagnosed as a ma...2019-12-2548 min
The Onco'Zine Brief with Peter HoflandCatherine Ivy: A Tireless Advocate for Brain Cancer PatientsIn this edition of The Onco’Zine Brief Peter Hofland talks with Catherine Ivy, the Founder and President of the Ben & Catherine Ivy Foundation.
The Ben & Catherine Ivy Foundation, established in 2005, is the largest non-government organization supporter of brain tumor - including glioblastoma (GBM) - research in the world. To date, the Ivy Foundation has funded clinical trials and basic science in North America, Europe, and Asia.
Glioblastoma, also known as glioblastoma multiforme, is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes, that support nerve cells. The disease can...2019-11-2342 min
The Onco'Zine Brief with Peter HoflandTARDIS - A Simple Blood Draw to Determining a Patient’s Response to Neoadjuvant TherapyIn this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Muhammed Murtaza and Dr. Thomas Slavin about liquid biopsies
Murtaza is Assistant Professor and co-Director of the Center for Noninvasive Diagnostics at TGen in Phoenix, AZ, and Dr. Slavin is Assistant Clinical Professor, Departments of Medical Oncology & Therapeutics Research and Population Sciences, Division of Clinical Cancer Genomics at City of Hope Comprehensive Cancer Center in Duarte, California.
Hofland talks with Murtaza and Slavin specifically about a test called TARDIS — which stands for TARgeted DIgital Sequencing. This test, according to a study published earlier this year, is as much...2019-11-2347 min
The Onco'Zine Brief with Peter HoflandHow does Checkpoint Inhibitor Therapy Work when there’s no Checkpoint Expressed on a Patient's CancerToday in The Onco’Zine Brief Peter Hofland talks with Dr. Michael Caligiuri and Deana and Steve Campbell Physician-in-Chief Distinguished Chair, President of City of Hope National Medical Center in Los Angeles, California, and Dr. Jianhua Yu, professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, and a Scholar of The Leukemia & Lymphoma Society.
By combining leading-edge science with true compassion and personalized treatment for each and every patient, scientists, researchers, doctors, nurses and in fact anyone at City of Hope, share in one single goal: Outsmarting cancer to eliminate it.
Recognizing the accomplishments in cancer rese...2019-08-0347 min
The Onco'Zine Brief with Peter HoflandBCAN's Mission to Increase Public Awareness, Advance Bladder Cancer Research and Support PatientsToday in The Onco’Zine Brief Peter Hofland talks with Diane Zipursky Quale.
Together with her late husband John Quale, Diane, who holds a BA from Stanford University and a JD from the National Law Center, George Washington University, is Co-Founder and Director of the Bladder Cancer Advocacy Network (BCAN), the only national advocacy organization devoted to advancing bladder cancer research and supporting those impacted by the disease.
BCAN is on the front-lines advocating for greater public awareness and increased funding for research to identify effective treatments and eventually, a cure for bladder cancer.
Each year, BCAN provides thousands of pa...2019-07-3148 min
The Onco'Zine Brief with Peter HoflandFinding Aswers and Improving Patient Care - How Genetic Tests can be Helpful (Part 2)In this edition of The Onco’Zine Brief Peter Hofland talks with Laura Panos Smith, a certified genetic counselor and vice president of commercial operations at Ambry Genetics.
Ms. Smith leads a large team responsible for the implementation of key strategic initiatives for Ambry Genetics.
This includes the daily support and education for patients and healthcare providers, as well as marketing and sales support functions.
Ms. Smith has been with Ambry Genetics since 2013 and she has held a number of positions, most recently as the National Director of the Genetic Specialist team – a position she held for three years.
Before join...2019-07-3147 min
The Onco'Zine Brief with Peter HoflandFinding Aswers and Improving Patient Care - How Genetic Tests can be Helpful (Part 1)In this edition of The Onco’Zine Brief Peter Hofland talks with Holly LaDuca, a certified genetic counselor and manager of clinical Research oncology at Ambry Genetics.
Identifying an individual’s genetic information is nothing new. And while, over the last decades, most people have become familiar with genetic ancestry testing, or genetic genealogy, as a way for people interested in their family history to go beyond what they can learn from relatives or from historical documentation, genetic testing is much more than that.
In essence, genomic data helps to accelerate the understanding of human disease.
Ambry Genetics, is a lead...2019-07-3143 min
The Onco'Zine Brief with Peter HoflandASCO 2019: Form Biomarker Discovery to Photo-ImmunotherapyIn this episode of the Onco’Zine Brief Peter Hofland reports from the 2019 annual meeting of the American Society of Clinical Oncology – ASCO – which was held May 31st – June 4th, 2019.
Hofland talks with:
- Dr. Hartmut Juhl, the Chief Executive Officer of Indivumed, a physician-led, integrated global oncology company. The company offers specialized products and services designed to support the discovery of biomarkers, drug development, clinical trials, and individualized treatment for patients with cancer, and
- Dr. Jeannie Hou, Vice President Clinical Development at Rakuten Medical, a company developing precision-targeted medicines through the development of a novel, proprietary photo-immunotherapy platform.
For more...2019-07-1741 minThe Onco'Zine BriefASCO 2019: Supportive Care and Developments in Gynecological CancerIn this episode of The Onco’Zine Brief, recorded during the annual meeting of the American Society of Clinical Oncology, ASCO, being held May 31 – June 4, 2019, Peter Hofland talks with Lee Schwartzberg MD, FACP, is a Medical Oncologist and Hematologist at West Cancer Center, Germantown, TN, and Dr. Shannon Westin, MD, MPH., FACOG, Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, a clinical investigator with a focus on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies.Today in The...2019-07-1544 min
The Onco'Zine Brief with Peter HoflandASCO 2019: The Courage and Expertese to Outsmarting CancerIn this episode of The Onco’Zine Brief Peter Hofland report from the annual meeting of the American Society of Clinical Oncology – ASCO – which was held May 31st – June 4th, 2019.
The American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. During the annual meeting Peter Hofland spoke with:
•Anna Protopapas, the president and Chief Executive Office of Mersana Therapeutics, a clinical stage biotech company developing antibody-drug conjugates – a very specific kind of targeted anti-cancer drug, I also talk with
•Eliran Malki, the Chief executive officer of BELONG.life, the world’s la...2019-07-1547 min
The Onco'Zine Brief with Peter HoflandASCO 2019: Supportive Care and Developments in Gynecological CancerIn this episode of The Onco’Zine Brief, recorded during the annual meeting of the American Society of Clinical Oncology, ASCO, being held May 31 – June 4, 2019, Peter Hofland talks with Lee Schwartzberg MD, FACP, is a Medical Oncologist and Hematologist at West Cancer Center, Germantown, TN, and Dr. Shannon Westin, MD, MPH., FACOG, Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, a clinical investigator with a focus on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies.
Today in The OncoZine Brie...2019-07-1544 min
The Onco'Zine Brief with Peter HoflandPatients Taking Back Control of their Own Healthcare InformationThis week The Onco’Zine Brief comes from Chicago, Illinois and the annual meeting of the American Society of Clinical Oncology (ASCO) being held May 31 – June 4, 2019. In this episode Peter Hofland talks with a Eugene Luskin, Chief Executive Officer of Redmond, Washington-based Vyrty.
As part of a growing push to let patients control and manage their own medical history, Luskin’s Vyrty has launched a mobile app called Sync.MD that is designed by healthcare professionals to lets users – patients - store and share their own medical records with doctors. The app is a Personal Health Records (PHR-) system operated directly o...2019-06-1546 min
The Onco'Zine Brief with Peter HoflandBeyond the Emergence of Targeted Therapies and the Treatment of Bladder CancerThis week The Onco’Zine Brief comes from Chicago, Illinois and the annual meeting of the American Society of Clinical Oncology (ASCO) being held May 31 – June 4, 2019.
In this episode Peter Hofland talks with a Adil Akhtar, MD, an Oncologist and Palliative Care Expert, Associate Professor, Department of Medical Oncology & Hematology at the Oakland University-William Beaumont School of Medicine. He is also director, of Inpatient Clinical Operations at the Karmanos-McLaren Oakland Cancer Center in Michigan and Chief, Division of Palliative & End of Life Care, Michigan Health Professionals.
Bladder Cancer
Bladder cancer is the sixth most common cancer in the U.S., with...2019-06-1047 min
The Onco'Zine Brief with Peter HoflandImproving the Effect of Anti-cancer Radiation and ChemotherapyIn this edition of The Onco’Zine Brief Peter Hofland talks with Greg Van Wyk, Chief Executive Officer and Chief Medical Officer of Noxopharm, a clinical-stage Australian drug development company with offices in Sydney, New York and Hong Kong.
The company is developing a number of drug candidates including an advanced dosage formulation of the generic anti-cancer agent called idronoxil, which is designed to specifically target cancer cells, rendering them less able to survive radiotherapy. The drug is marketed as Veyonda®
Radiation seeks to kill cancer cells by damaging their DNA beyond any ability of the cancer cell to repair tha...2019-05-3047 min
The Onco'Zine Brief with Peter HoflandA New Combination Therapy may help Stop Triple Negative Breast Cancer from SpreadingIn this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Salman Hyder, Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center at the University of Missouri, in Columbia, Missouri.
Together with a team of researchers Dr. Hyder found that a combination drug therapy, reduces the spread of triple negative breast cancer to other locations of the body by 50%
A breast cancer cell is like a house with three locks on the front door. Keys, or receptors, allow drugs to unlock the door and kill the ce...2019-05-3044 min
The Onco'Zine Brief with Peter HoflandBetter Pain Management Improves Health Related Quality of Life (hrQoL)In this edition of The Onco’Zine Brief Peter Hofland talk with Dr. Lisa Stearns, the founder and medical director of Center for Pain and Supportive Care, in Phoenix, Arizona.
An internationally recognized Interventional Pain Specialist, board certified in hospice and palliative medicine and pain management, Dr. Stearns’ passion for changing the face of acute and chronic pain-treatment is evidenced by her ongoing care for her patients and her active research to find a better way to manage pain.
In addition to her work at the Center for Pain and Supportive Care, Dr. Stearns has authored numerous research articles and freq...2019-05-3047 min
The Onco'Zine Brief with Peter HoflandImmuno-Oncology: Augmenting the Immune System’s Natural Ability to See and Eliminate CancerIn this edition of The Onco’Zine Brief Peter Hofland talks with Mr. Isaac Israel, the CEO of Kitov Pharma, a pharmaceutical drug development company developing new options to treat osteoarthritis pain and hypertension simultaneously, as well as novel anticancer drugs.
The company is developing an investigational drug called NT-219, a novel small molecule drug designed to targets two signal proteins that are part of an anti-cancer drug resistance mechanism.
Based on recent findings, Kitov researchers demonstrated that NT-219 binds directly to the two proteins.
In previous preclinical models where NT-219 was administered in combination with various oncology therapies, outstanding effi...2019-05-3048 min
The Onco'Zine Brief with Peter HoflandEnding the Opioid Crisis: How Targeted Drug Delivery May Improve Pain ManagementIn this edition of The Onco’Zine Brief Peter Hofland talks with Charlie Covert, Vice President & General Manager Targeted Drug Delivery, Restorative Therapies Group - Pain Division at Medtronic, about opioids and pain management in patients with cancer.
While considered safe, reliable, and effective for all types of pain, opioids are also a potentially abuseable drugs. And the public health consequence of opioid abuse, is really bad.
More than 11.5 million people abused prescription opioids. As a result, every day, more than 1,000 people are treated in emergency departments for misusing prescription opioids.
The Centers for Disease Control and Prevention estimates the to...2019-05-0347 min
The Onco'Zine Brief with Peter HoflandGet a Colonoscopy, Prevent Colorectal CancerIn this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Kenneth Vega, chief of Gastroenterology and co-director of the Digestive Health Center at Augusta University Health, a public research university and academic medical center located in Augusta, Georgia (USA).
Hofland and Vega talk about the prevention of colorectal cancer by means of a colonoscopy.
Unfortunately, many people postpone or refuse a colonoscopy because of fear.
Dr. Vega, one of the newest members of the Digestive Health Center at Augusta University in Georgia, has made it his mission to turn anxiety, fear and stress about the procedure into pe...2019-04-2343 min
The Onco'Zine Brief with Peter HoflandA Bold Approach to Identify New and Effective Therapies for Malignant Brain TumorsIn this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Nader Sanai an internationally-recognized neurosurgical oncologist with clinical and research expertise in the treatment of all brain tumors, including glioblastoma, the most aggressive cancer that begins within the brain.
Dr. Sanai is the director of the Ivy Brain Tumor Center at the Barrow Neurological Institute in Phoenix, Arizona. He is also the principal architect of the Center’s accelerated clinical trials program, the largest in the word.2019-04-0948 min
The Onco'Zine Brief with Peter HoflandCuring America's Unpayable Trillion Dollar Healthcare DebtIn this edition of The Onco’Zine Brief Peter Hofland talks with Robert Goff about Medical Debt. Goff is one of the co-authors of a new book (“End Medical Debt: Curing America’s $1 Trillion Unpayable Healthcare Debt”) about the subject. He co-authored the book with Jerry Ashton and Craig Antico.
In today's show Hofland and Goff talk about the problem of medical debt and how we got here. They talk about the impossibility of making insurance coverage broad and affordable when the cost of medical services is so prohibitive.
And finally, they talk about how "RIP Medical Debt," the organization he repre...2019-04-0548 min
The Onco'Zine Brief with Peter HoflandNational Colorectal Cancer Awareness Month 2019 (Part 2)In the second part of a 3-part series about colorectal cancer, developed in collaboration with the online journal OncoZine at www.oncozine.com, Peter Hofland, PhD. talks with Paul J. Berggreen, MD and Daniel M. Jondle, MD, both from Arizona Digestive Health, in Phoenix, Arizona, and Sukhdeep S Padda, MD from Arizona Gastrointestinal Associates and Arrowhead Gastroenterology Associates, in Glendale, Arizona.
Colorectal Cancer is also the second leading cause of death from cancers that affect both men and women. According to the American Cancer Society, the overall lifetime risk of developing colorectal cancer is: about 1 in 22 for men and 1 in 24...2019-04-0145 min
The Onco'Zine Brief with Peter HoflandNational Colorectal Cancer Awareness Month 2019 (Part 3)In the third and final part of a 3-part series about colorectal cancer, developed in collaboration with the online journal OncoZine at www.oncozine.com, Peter Hofland, PhD. talks with Paul J. Berggreen, MD and Daniel M. Jondle, MD, both from Arizona Digestive Health, in Phoenix, Arizona, and Sukhdeep S Padda, MD from Arizona Gastrointestinal Associates and Arrowhead Gastroenterology Associates, in Glendale, Arizona.
Colorectal Cancer is also the second leading cause of death from cancers that affect both men and women. According to the American Cancer Society, the overall lifetime risk of developing colorectal cancer is: about 1 in 22 for men...2019-04-0140 min
The Onco'Zine Brief with Peter HoflandCannabinoid-based Drug Discovery and Development Designed to Benefit Cancer PatientsThis week in The Onco’Zine Brief Peter Hofland, Ph.D talks with Guy Chamberland, M.Sc., Ph.D, about medicinal cannabis.
Chamberland, is a Master Herbalist as well as Chief Executive Officer and Chief Scientific Officer of Tetra Bio-Pharma, a biopharmaceutical company developing cannabinoid-based drugs.
Tetra Bio-Pharma has a clinical development program aimed at bringing novel drugs and treatments to patients and their healthcare providers.
To do this, the Company has several subsidiaries that are engaged in the development of Bio Pharmaceutical drugs and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on...2019-04-0148 min
The Onco'Zine Brief with Peter HoflandNational Colorectal Cancer Awareness Month: Prevention, Diagnosis and Treatment (Part 1)In this edition of The Onco’Zine Brief Peter Hofland talks with Dr. Paul Berggreen and Dr. Daniel Jondle, both from Arizona Digestive Health, in Phoenix, Arizona, about Colorectal Cancer.
Today’s program is the first of a 3-part series about the disease, which is the third most common cancer diagnosed in the United States. Colorectal Cancer is the second leading cause of death from cancers that affect both men and women. And the disease affects people in all racial and ethnic groups and is most common in people age 50 and older.
But in many cases the disease is preventable.
And...2019-03-0648 min
The Onco'Zine Brief with Peter HoflandRevolutionizing the Manufacturing of Antibody-Drug Conjugates - A Conversation with ADC Bio's Charlie JohnsonIn this edition of The Onco’Zine Brief Peter Hofland talks with Charlie Johnson, Chief Executive Officer of ADC Bio, a biotechnology company, specialized in the development of Antibody-drug Conjugates.
Antibody-drug Conjugates, also known as ADCs, are a novel type of targeted anticancer agents. Today 4 drugs in this class of drugs have been approved by regulators around the world, but there are more than 150 investigational agents in this class of drugs in development.
The antibody used in an Antibody-drug Conjugate or ADC specifically target cancer cells. This approach offers various advantages over current therapies based on standard chemotherapeutic drugs currently us...2019-02-2740 min
The Onco'Zine Brief with Peter HoflandImproving Treatment for Patients with Pancreatic CancerIn this Edition of the OncoZine Brief, recorded during the Annual meeting of American Society of Clinical Oncology (ASCO), which took place June 1-5, 2018 in Chicago Illinois, Peter Hofland and Sonia Portillo interview Dr. Sotirios Stergiopoulos, who is the Chief Medical Officer of Ipsen, a global specialty-driven biopharmaceutical group focused on innovation and specialty care.
The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a we...2018-07-0639 min
The Onco'Zine Brief with Peter HoflandAdvancing Treatment for Patients with Advanced Triple Negative Breast CancerIn this edition of The Onco’Zine Brief, recorded during the Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, June 1 - 5, 2018, Peter Hofland and Sonia Portillo talk with Michael Pehl, President and Chief Executive Officer of Immunomedics, a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC).
At this year’s ASCO meeting, nearly 40,000 attendees gathered to discuss the growing body of data on advanced, difficult to treat diseases that do not have many treatment options.
Hofland and Portillo speak with Pehl about some of the exciting developments that are taking place at this...2018-06-3039 minThe Onco'Zine BriefResults from ASCO 2018: Expanding the Reach of Precision Medicine (Part 1)This week in The Onco’Zine Brief Peter Hofland and Sonia Portillo talk with experts in oncology about some of the results presented during the annual meeting for the American Society of Clinical Oncology, held in Chicago, Ill, June 1 - 5, 2018.The theme of this year’s ASCO conference is: Delivering Discoveries: Expanding the Reach of Precision Medicine. More than 40,000 people attended the meeting.Hofland and Portillo interview Robert Dreicer, MD, MS, MACP, FASCO, the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Cancer Center. Dreicer shares his perspective on a high...2018-06-2838 min
The Onco'Zine Brief with Peter HoflandResults from ASCO 2018: Expanding the Reach of Precision Medicine (Part 1)This week in The Onco’Zine Brief Peter Hofland and Sonia Portillo talk with experts in oncology about some of the results presented during the annual meeting for the American Society of Clinical Oncology, held in Chicago, Ill, June 1 - 5, 2018.
The theme of this year’s ASCO conference is: Delivering Discoveries: Expanding the Reach of Precision Medicine. More than 40,000 people attended the meeting.
Hofland and Portillo interview Robert Dreicer, MD, MS, MACP, FASCO, the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Cancer Center. Dreicer shares his perspective on a highly-anticipated presentations dealing with raci...2018-06-2838 min
The Onco'Zine Brief with Peter HoflandImproving the Clinical Outcomes of Patients with Gastrointestinal IllnessIn this Edition of the Onco'Zine Brief, Peter Hofland and Sonia Portillo talk with Dr. John B. Kisiel, Assistant Professor of Medicine and a Consultant in the, Division of Gastroenterology and Hepatology, Department of Internal Medicine at the Mayo Clinic in Rochester, Minnesota.
The overall goal of Dr. Kisiel is to improve the clinical outcomes of patients with gastrointestinal illness by providing excellent bedside care and conducting clinical and translational research. His primary research focus is the prevention and early diagnosis of cancers and pre-cancers in high-risk patients.
In today’s program Hofland and Portillo talk with Dr Kisiel about fi...2018-06-2839 min
The Onco'Zine Brief with Peter HoflandDelivering Discoveries and Expanding the Reach of Precision Medicine: A Preview ASCO 2018In the edition of The Onco’Zine Brief Peter Hofland and Sonia Portillo review some of the most exciting and important study to be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), to be held in Chicago, June 1 - 5, 2018.
The theme of this year’s conference is: Delivering Discoveries: Expanding the Reach of Precision Medicine. More than 2,500 abstracts were accepted for presentation while an additional 3,350 abstracts were accepted for online publication.
Approximately 40,000 oncology professionals from around the world will be attending this meeting.2018-06-2840 min
The Onco'Zine Brief with Peter HoflandA Distinguished Public Service Award for Exceptional Leadership in Cancer Advocacy InterviewIn this episode of the Onco’Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Col. James E. Williams who, during the annual meeting of the American Association for Cancer Research (AACR), held April 14 - 18, 2018 in Chicago, Ill, received the organization's Distinguished Public Service Award for Exceptional Leadership in Cancer Advocacy.
Each year, the American Association for Cancer Research presents Special Recognition Awards to four individuals whose work made extraordinary contributions to the organization’s mission to accelerate the prevention and cure of all cancers through research, education, communication, and collaboration.
These AACR Awards recognize groundbreaking, innovative work acro...2018-05-2639 min
The Onco'Zine Brief with Peter HoflandTransforming Cancer to a Treatable Disease: An Interview with Dr. Elizabeth M. JaffeeIn this edition of The Onco’Zine Brief Peter Hofland and Sonia Portillo are talking with Elizabeth M. Jaffee, MD, the 2018 - 2019 president of the American Association for Cancer Research (AACR).
Dr. Jaffee’s, who's research is focused on the development of immune based therapies for pancreatic and breast cancers, is the deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. She is also the leader of the Stand Up To Cancer (SU2C)-Lustgarten Foundation Dream Team: Transforming Pancreatic Cancer to a Treatable Disease.
In their interview, recorded during the annual meeting of the AACR...2018-05-1935 minThe Onco'Zine BriefAddressing Key Challenges in Cancer Diagnostics and Treatment: Cancer Health DisparitiesToday in The Onco’Zine Brief Peter Hofland and Sonia Portillo talk with Dr. Michael Caligiuri., MDThe Interview was recorded during the 2018 annual meeting of American Association for Cancer Research (AACR) held April 14-18th, 2018 in Chicago, Illinois.Michael A. Caligiuri is a renowned physician-scientist known for his work in immunology that is focused on human natural killer cells and their modulation for the treatment of leukemia, myeloma, and glioblastoma. To date over 1,500 cancer patients have been treated on clinical protocols that have originated from the Dr. Caligiuri laboratory.Dr. Caligiuri is the pres...2018-05-1638 min
The Onco'Zine Brief with Peter HoflandThe Importance of Oral Care – and the Link with Cancer and Cancer TreatmentToday in the OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Jim Ratcliff, CEO of Chairman of Rowpar Pharmaceuticals, the developer, manufacturer and marketer of best-in-class oral care products, sold under the CloSYS brand in Australia and the United States and under private label in Europe and India.
In their interview with Dr.Ratcliff, Hofland and Portillo ask about the importance of oral care – and the link with cancer.
Patients receiving treatment for cancer can experience a number of potential side effects in response to the treatment they receive. Most clinicians and patients are aware of the ad...2018-05-1639 min
The Onco'Zine Brief with Peter HoflandAddressing Key Challenges in Cancer Diagnostics and Treatment: Cancer Health DisparitiesToday in The Onco’Zine Brief Peter Hofland and Sonia Portillo talk with Dr. Michael Caligiuri., MD
The Interview was recorded during the 2018 annual meeting of American Association for Cancer Research (AACR) held April 14-18th, 2018 in Chicago, Illinois.
Michael A. Caligiuri is a renowned physician-scientist known for his work in immunology that is focused on human natural killer cells and their modulation for the treatment of leukemia, myeloma, and glioblastoma. To date over 1,500 cancer patients have been treated on clinical protocols that have originated from the Dr. Caligiuri laboratory.
Dr. Caligiuri is the president and physician-in-chief of City of Hope...2018-05-1638 min
The Onco'Zine Brief with Peter HoflandDr. Otis Brawley: Meeting the Challeng of Attacking Cancer from Every AngleThis week in The Onco’Zine Brief: Peter Hofland, Ph.D and Sonia Portillo talk with Otis Brawley, MD, MACP the Chief Medical and Scientific Officer of the American Cancer Society.
Hofland and Portillo ask Dr. Brawley about the past, present, and future of the fight against cancer, including screening, diagnostics and treatment with novel, targeted drugs, and the role of the American Cancer Society in helping to prevent cancer.
In today’s interview they further address some of the most pressing issues in oncology today, such as cancer health disparities and access to healthcare in lower income areas, as well...2018-05-1539 min
The Onco'Zine Brief with Peter HoflandA New Frontline Treatment Option for Hodgekin LymphomaIn this Edition of The Onco'Zine Brief Peter Hofland, Ph.D and Sonia Portillo talk with Joseph M. Connors, MD., FRCPC, Clinical Director, Center for Lymphoid Cancer (Retired 2018) and Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency
Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma.
In this interview Dr. Connor talks about the some of the latest results from the ECHELON-1 clinical...2018-05-1440 min
The Onco'Zine Brief with Peter HoflandEarly Detection of Solid Tumor Based CancersIn this Edition of the OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Amit Kumar, Ph.D, Chairman, President & Chief Executive Officer of ITUS Corporation Executive Chairman of Anixa Diagnostics Corporation
Dr. Kumar, is the inventor of the company’s Cchek™ technology for the early detection of tumor-based cancers and has been an investor, founder, director and CEO of several technology enterprises, both public and private.
In today’s program Hofland and Portillo talk with Dr. Kumar about cancer, the evolution of cancer diagnostics since the signing of the National Cancer Act and the start of the ‘War on c...2018-05-1441 min
The Onco'Zine Brief with Peter HoflandImproving Targeted Therapies for Patients with Previously Untreated Advanced Classic Hodgkin LymphomaIn this episode of The Onco'Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Dr. Joseph M. Connors, MD., FRCPC, Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency.
Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma.
In this interview Hofland and Portillo talks with Dr. Connor about some of the latest results from the ECHELON-1 clinical trial, which tests an...2018-04-0839 min
The Onco'Zine Brief with Peter HoflandA Novel Treatment Option for Hepatocellular CarcinomaIn this episode of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Gisela Schwab, MD, President, Product Development and Medical Affairs and Chief Medical Officer at Excelixis.
Following early work in model genetic systems, Exelixis, a genomics-based drug discovery company located in South San Francisco, CA, established a broad drug discovery and development platform that has served as the foundation for the company’s continued efforts to bring new cancer therapies to patients in need. The company discovered and developed its lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships wi...2018-03-2539 min
The Onco'Zine Brief with Peter HoflandThe Development of Probody Therapeutics for the Targeting of CancerIn this edition of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk Sean McCarthy, D.Phil, President and Chief Executive Officer of CytomX, a biotechnology company developing a novel 'Probody Platform' which allows them to design therapeutic drugs that selectively activate in the tumor microenvironment while reducing drug activity in healthy tissue and in circulation.
In addition to his work for CytomX, McCarthy is the author on multiple peer-reviewed scientific publications, issued patents and filed patent applications.
CytomX is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted...2018-03-2537 min
The Onco'Zine Brief with Peter HoflandComputational Oncology and Tumor Modeling - The Next Phase in Personalized Therapies for Cancer PatientsIn this episode of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Thomas Yankeelov, Ph.D, a computational biomedical engineer who came to The University of Texas at Austin from Vanderbilt University, where he served as the Ingram Professor of Cancer Research; professor of radiology and radiological sciences, physics, biomedical engineering and cancer biology; and director of cancer imaging research. He also served as a co-leader of the Host-Tumor Interactions Research Program for the Vanderbilt-Ingram Cancer Center.
Thomas Yankeelov serves as Director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School...2018-03-2541 minThe Onco'Zine BriefA Cure Within - Understanding the Power of the Immune System in the Treatment of CancerIn this episode of The Onco’Zine Brief Peter Hofland, Ph.D and Sonia Portillo are speaking with Joshua A. Hill, MD, an Associate in Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center in Seattle Washington. Dr. Hill is also an attending physician at the Seattle Cancer Care Alliance, as well as an Assistant Professor at the University of Washington.In today's show Hofland and Portillo ask Dr. Hill about CAR T cell therapy- a technology that holds very high expectations for the future of cancer care. In a number of clinical trials in certain severe ca...2018-03-0538 min
The Onco'Zine Brief with Peter HoflandPogress in the Treatment of Multiple Myeloma - An Interview with Dr. Noopur RajeIn this edition of The OncoZine Brief, Peter Hofland, Ph.D and Sonia Portillo review some of the interesting studies presented at the 59th annual meeting of the American Society of Hematology – which took place December 9 – 12, 2017 in Atlanta, Georgia.
They recap one of the most important healthcare conferences of the year, the annual meeting American Society of Hematology or ASH, one of these ‘must go to’ meetings for oncology and hematology specialists but also for oncology nurses, researchers, and patients alike.
In this episode they also interview Noopur Raje, MD, Associate Professor of Medicine at Harvard Medical School; Director of the Mult...2018-03-0527 min
The Onco'Zine Brief with Peter HoflandA Cure Within - Understanding the Power of the Immune System in the Treatment of CancerIn this episode of The Onco’Zine Brief Peter Hofland, Ph.D and Sonia Portillo are speaking with Joshua A. Hill, MD, an Associate in Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center in Seattle Washington. Dr. Hill is also an attending physician at the Seattle Cancer Care Alliance, as well as an Assistant Professor at the University of Washington.
In today's show Hofland and Portillo ask Dr. Hill about CAR T cell therapy- a technology that holds very high expectations for the future of cancer care. In a number of clinical trials in certain severe cancer types, CA...2018-03-0538 min
The Onco'Zine Brief with Peter HoflandPhill Rowlands: A Focus on Global R & DIn this Edition of The OncoZine Brief, brought to you from the 59th annual meeting of the American Society of Hematology held December 9-12, 2017 in Atlanta, Georgia, Peter Hofland, Ph.D and Sonia Portillo, B.Sc, the team behind the show, sat down with Phill Rowlands, Vice President and Head Oncology Therapeutic Area unit as well as Drug Development Management and Portfolio Management at Takeda Pharmaceuticals in Cambridge, Massachusetts, United States.
Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. The company focuses...2018-02-0543 minThe Onco'Zine BriefA Dramatic Progress in New Drug Development Maximizes Patient BenefitFor this edition of The Onco'Zine Brief, recorded during 59th annual meeting of the American Society of Hematology held December 9 to 12, 2017 in Atlanta, Georgia, Peter Hofland and Sonia Portillo, the team behind show, sat down with Steven E. Benner, M.D., Senior Vice President and Therapeutic Area Head for Oncology at Astellas Pharma.In this interview Hofland and Portillo asks Benner about the many changes at Astellas, the company’s focus and some of the greatest challenges the company faces. They also talk about the definition of personalized medicine, precision medicine and targeted therapies – and the differences of thes...2018-01-2838 min
The Onco'Zine Brief with Peter HoflandA Dramatic Progress in New Drug Development Maximizes Patient BenefitFor this edition of The Onco'Zine Brief, recorded during 59th annual meeting of the American Society of Hematology held December 9 to 12, 2017 in Atlanta, Georgia, Peter Hofland and Sonia Portillo, the team behind show, sat down with Steven E. Benner, M.D., Senior Vice President and Therapeutic Area Head for Oncology at Astellas Pharma.
In this interview Hofland and Portillo asks Benner about the many changes at Astellas, the company’s focus and some of the greatest challenges the company faces. They also talk about the definition of personalized medicine, precision medicine and targeted therapies – and the differences of these approaches beyo...2018-01-2838 min
The Onco'Zine Brief with Peter HoflandA new Paradigm in the Development and Manufacturing of Antibody-drug ConjugatesRecorded during CPhI World Wide, October 24 - 27, 2017 in Frankfurt Germany, Peter Hofland and Sonia Portillo interview Charlie Johnson, the CEO of ADC Bio. ADC Bio, a biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of novel anti-cancer blockbuster drugs known as Antibody-drug Conjugates or ADCs.2017-12-1626 min
The Onco'Zine Brief with Peter HoflandThe I-SPY Clinical Trial Program: Building a Pipeline of Novel Anticancer AgentsIn this episode of The Onco’Zine Brief hosts Peter Hofland, Ph.D and Sonia Portillo talk with Angela M. DeMichele, MD MSCE, Professor of Medicine and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania.
Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs.
The development of these promising new therapeutic agents is generally based on preclinical and clinical research. In many cases, this research has, become prohibitively expensive. And only a relatively few investigational drugs have reached the market and successfully improved clinical outcomes in the treatment of pa...2017-12-1633 min
The Onco'Zine Brief with Peter HoflandDr. Robert Orlowski: Progress in the Treatment of Multiple MyelomaIn this episode of The Onco'Zine Brief, Sonia Portillo and Peter Hofland ask Robert Z. Orlowski, MD, PhD, chairman, Ad Interim, Director of Myeloma and professor of Medicine in the Departments of Lymphoma, Myeloma and Experimental Therapeutics in the Division of Cancer Medicine at MD Anderson in Houston, Texas, about his thoughts and unique perspective on research and the recent advancements in the treatment multiple myeloma, including promising results with a drug called carfilzomib (marketed as Kyprolis® by Amgen), which has become the first treatment proven to extend the overall survival of patients with relapsed multiple myeloma when compared to t...2017-12-1646 min
The Onco'Zine Brief with Peter HoflandFred R. Hirsch, MD, PhD: The Impact of New Therapies in the Treatment of Lung CancerLung cancer remains one of the most frequently diagnosed cancers. It is also one of the deadliest cancers – with each year more than 1.6 million tumor-related deaths worldwide.
The correlation between smoking and mortality from lung cancer has been clearly confirmed and a decrease of mortality after cessation of tobacco use has been seen in the United States…
Since the 1990s first in men and later, since the early 2000s also in women. Although direct environmental exposure to tobacco smoke is the predominant risk factor, inhalation of cancer causing agents such as marijuana or hookah us also contributes to the risk of l...2017-12-1642 min
The Onco'Zine Brief with Peter HoflandSuperblood: The Development of Novel Red-Cell TherapeuticsIn an Interview with Sonia Portillo and Peter Hofland, the team behind The Onco'Zine Brief, David R. Epstein BSc, MBA, the Executive Chairman of Rubius Therapeutics, explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.
Epstein explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.2017-12-1633 min
The Onco'Zine Brief with Peter HoflandBonnie J. Addario: An Urgent Need to Impact Lung Cancer Care in a Big WayEach year, 1.4 million people are diagnosed with lung cancer worldwide. The 5-year survival rate for these patients is only 15.9%.
In this episode, Sonia Portillo and Peter Hofland, the team behind The Onco'Zine Brief, interview Bonnie Adario, Cancer Survivor.
Addario was was first diagnosed with stage 3b lung cancer in 2004, a cancer with a survival rate of only 5%. As part of her treatment, Addario underwent surgery to remove one lobe, radiation and chemotherapy treatments, and, against the odds, became a lung cancer survivor.
After this experience, she felt an urgent need to impact lung cancer care in a big way.
In 2006...2017-12-1629 min
The Onco'Zine Brief with Peter HoflandFocusing on Hard to Treat Cancers: An Interview with Astellas' Dr. Steve Benner and Mark ReisenauerRecorded during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 2 - 6, 2017 in Chicago, Ill, Sonia Portillo and Peter Hofland, the team behind The Onco'Zine Brief, interview Dr. Steve Benner – Senior Vice President and Therapeutics Area Head of Oncology at Astellas Pharmaceuticals, and Mark Reisenauer, Senior Vice President, Oncology business unit at Astellas Pharmaceuticals.
Astellas currently has several highly targeted drugs in development and clinical trials, one of which is enfortumab vedotin, which is demonstrating promising results for metastatic urothelial cancer patients that fail checkpoint inhibitor therapies or CPIs.
Enfortumab vedotin is an investigational antibody-drug co...2017-12-1627 min
The Onco'Zine Brief with Peter HoflandNovel Drugs Leading the Way to Progress in the Treatment of Multiple MyelomaIn this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo talk with Robert Z. Orlowski, MD, PhD, chairman, Ad Interim, Director of Myeloma and Professor of Medicine in the Departments of Lymphoma, Myeloma and Experimental Therapeutics in the Division of Cancer Medicine at MD Anderson in Houston, Texas.
They ask Orlowski about his thoughts and unique perspective on research and the recent advancements in the treatment multiple myeloma (a type of blood cancer), including promising results with a drug called carfilzomib (marketed as Kyprolis® by Amgen), which has become the first treatment proven to extend the overall survival o...2017-12-1646 min
The Onco'Zine Brief with Peter HoflandThe Onco'Zine Brief: Nano-Pulse Stimulation (NPS)In this episode of The OncoZine Brief host Peter Hofland interviews Darrin Uecker and Richard Nuccitelli of Pulse Biosciences.
The team at Pulse Biosciences has developed a technology is called Nano-pulse Stimulation, or NPS. This novel technology delivers ultra-short nanosecond pulses to stimulate cellular responses in targeted tissue. These pulses induce cells to die in a natural way.
Preclinical studies indicate that NPS can stimulate the adaptive immune response, commonly known as immunogenic cell death. The new technology thus engages the immune system to clear away damaged, diseased, or aged cells and recruit cancer-attacking T cells to the tumor site.
...2017-07-1429 min